Long-acting pasireotide improves clinical signs and quality of life in Cushing’s disease: results from a phase III study

Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN

(2018) Elena Valassi et al.   CLINICAL ENDOCRINOLOGY

Morbidity of Cushing’s Syndrome and Impact of Treatment

(2018) Susan M. Webb et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial

(2018) André Lacroix et al.   Lancet Diabetes & Endocrinology

Diabetes Mellitus Secondary to Cushing’s Disease

(2018) Mattia Barbot et al.   Frontiers in Endocrinology

Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing’s disease

(2018) M. A. Minetto et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Complications of Cushing's syndrome: state of the art

(2016) Rosario Pivonello et al.   Lancet Diabetes & Endocrinology

Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study

(2016) Richard N Clayton et al.   Lancet Diabetes & Endocrinology

The Treatment of Cushing's Disease

(2015) Rosario Pivonello et al.   ENDOCRINE REVIEWS

Using subscales when scoring the Cushing's quality of life questionnaire

(2015) Jitske Tiemensma et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Metabolic comorbidities in Cushing's syndrome

(2015) Francesco Ferraù et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

(2015) Lynnette K. Nieman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cushing's syndrome

(2015) André Lacroix et al.   LANCET

Comorbidities in Cushing’s disease

(2015) S. T. Sharma et al.   Pituitary

Reducing the Blood Pressure–Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and Control

(2015) Shakia T. Hardy et al.   Journal of the American Heart Association

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

(2014) Rosario Pivonello et al.   CLINICAL ENDOCRINOLOGY

Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers

(2013) Robert R. Henry et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations

(2013) Annamaria Colao et al.   Pituitary

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects

(2012) R A Feelders et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

(2012) Annamaria Colao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mortality and Morbidity in Cushing's Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature

(2010) R. N. Clayton et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease

(2010) Richard A. Feelders et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire

(2008) S M Webb et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY